Stocklore

ZOETIS INC. (ZTS)

Biotech & Health · US stock

What changed this quarter

  • Risk factors — 4 added · 2 removed · new: Changes in trade policies, including the im… +3
  • Free cash flow declined recently

What changed in recent SEC filings — factual, not a buy/sell recommendation.

Company overview

Zoetis. The world's No. 1 in animal medicine. It supplies vaccines and drugs for pets and livestock, maintaining stable growth.

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

ZOETIS INC. is classified under the Biotech & Health sector. See peers below.

ZOETIS INC. key financials

Based on SEC filings · latest quarter (TTM)

Tap a metric name to see its meaning in the glossary.

ETFs holding ZOETIS INC.

Per SEC N-PORT · 2026-03-31 · by weight · factual

XLVState Street(R) Health Care Select Sector SPDR(R) ETF
0.94%
VYMVANGUARD HIGH DIVIDEND YIELD INDEX FUND
0.21%
RSPInvesco S&P 500 Equal Weight ETF
0.21%
VOOVANGUARD 500 INDEX FUND
0.09%
IVViShares Core S&P 500 ETF
0.09%
SPY
0.09%
ITOTiShares Core S&P Total U.S. Stock Market ETF
0.08%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
0.07%

ZTS on Stocklore

  • Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
  • Sector-relative metrics — valuation and growth vs the Biotech & Health average
See full ZTS analysis →

Peers · Biotech & Health

ZTS FAQ

What is ZOETIS INC. (ZTS)?

Zoetis. The world's No. 1 in animal medicine. It supplies vaccines and drugs for pets and livestock, maintaining stable growth.

What sector is ZOETIS INC. in?

ZOETIS INC. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

What are ZOETIS INC.'s key financials?

Based on the latest quarter (TTM) from SEC filings: Revenue growth (YoY) 2.6%, Net margin 27.8%, ROE 80.2%, Debt-to-equity 2.71x. Definitions and interpretation are available on Stocklore.

Where can I analyze ZOETIS INC. (ZTS) stock?

On Stocklore you can see ZTS's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

Stocklore · CEO Lee Seung-jae · Business reg. no. 764-36-01607 · E-commerce permit 2026-Jeonju Wansan-0476 · Tel +82-70-7954-4939 · S120, Rm 302, 3F, 21 Jungsanjungang-ro, Wansan-gu, Jeonju, Jeonbuk, Korea